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Prolongation of QT/QTc interval during medical treatment can occur not only with
cardiovascular drugs but also with non-cardiovascular drugs. It may result in ventricular
tachyarrhythmia, a high-risk condition which may trigger sudden cardiac death. Thus, to
avoid drug-induced long QT syndrome and serious complications careful attention should be
paid in the clinical setting.
Moreover, in the last several years objective evaluation by strictly applying electrocardio-
gram (ECG) data has been strongly recommended for the development of all new drugs in
discussions held at the International Conference on Harmonization (ICH). This recommen-
dation has already been adopted in the USA and the EU and is expected to be announced
shortly in our country.
Not only the drugs but a variety of patient background factors may inﬂuence ECG
parameters, especially the QT/QTc interval. It is necessary to introduce an appropriate study
protocol that can evaluate the risk for QT/QTc prolongation related to the drug. Additionally,
an adequate system to record, measure, and evaluate ECG with high objectivity must be
applied to all clinical trials.
(J Arrhythmia 2009; 25: 56–62)
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Introduction
Drug-induced prolongation of QT interval has
recently received intensive attention in the clinical
setting, because it may be followed by the appear-
ance of torsade de pointes-type ventricular arrhyth-
mias (Tdp), sometimes resulting in sudden cardiac
death.1–3) It is thought that the most likely candidate
for the mechanism responsible for the prolongation
of the QT interval is a suppression of the IKr current
through the K channel (h-ERG channel) of myocar-
dial cell, resulting in the prolongation of the action
potential duration of ventricular myocytes. An
excess prolongation of action potential may some-
times cause triggered activity due to early after-
depolarization at phase 3 of the action potential that
is thought to be a trigger of Tdp.
Class III antiarrhythmic drugs including sotalol,
nifekalant, dofetilide and amiodarone exhibit a
potent blocking action on IKr as their principal
pharmacological eﬀects, and may exert signiﬁcant
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QT/QTc prolongation in the course of routine
treatment with the drugs. Because these eﬀects are
well known and are expected beforehand, QT/QTc
prolongation should be checked and managed
throughout the therapy. However, not only these
class III drugs but many other drugs that are used for
non-cardiac purposes are also known to the latent
eﬀect of prolonging the QT interval. Besides, we
know that many non-pharmacological factors sur-
rounding the patients may have an inﬂuence on
electrocardiographic parameters including the QT
interval. Are drugs always entirely responsible for
QT prolongation during medical therapy? Do we
have a deﬁnite answer to this question?
Deﬁnition of Drug-Induced Long QT Syn-
drome
When we observe excess QT/QTc prolongation
during a certain medical therapy, drug-induced long
QT syndrome should be highly suspected, even with
non-cardiac drugs.4) In strict terms, drug-induced
long QT syndrome is deﬁned as QT/QTc interval
prolongation greater than the normal range due to
direct pharmacological action to the myocardial cell.
However, it may be diﬃcult to deﬁnitely diﬀer-
entiate QT/QTc prolongation associated with a
direct eﬀect of the drug on the myocardium from
the eﬀect of the drug on other tissues or organs with
no eﬀect on myocardial cells. For example, we
sometimes ﬁnd that the QT/QTc interval has been
prolonged by loop diuretic agents associated with
lowering the serum [K+] level. Also, we may not be
able to diﬀerentiate the eﬀect on QT/QTc prolon-
gation of various acquired factors including brady-
cardia, myocardial ischemia, cerebrovascular dis-
eases, and electrolyte imbalance, as listed in Table 1,
from that of drugs only.
We must assume that there are no drugs which
never prolong the QT/QTc interval under any
conditions and that all patients who are taking any
kind of drugs have a risk for QT/QTc prolongation.
However, in the real world, it is not appropriate to
check ECG at every hospital visit in all patients.
Practically, it is important to know which types of
drugs have the potential to prolong QT/QTc interval
due to their K channel blocking action under usual
clinical dosage.
Table 2 is a list of drugs other than class III
antiarrhythmic agents with the potential for prolon-
gation of QT/QTc interval as reported in the
literature.5,6) Not only drugs for cardiovascular dis-
eases including Na channel blocking agents and anti-
anginal drugs, but also many other drugs for non-
cardiovascular use such as neuroleptics, antidepres-
sants, antihistamines, antibiotics, and antineoplastics
are listed. We have to be very careful to see that the
list is never complete. It is thought that many drugs
not on this list might prolong QT/QTc interval. This
list should be considered the ‘‘tip of an iceberg.’’
Problems of QT/QTc Prolongation due to Non-
Cardiovascular Drugs
It is sometimes very diﬃcult to check QT/QTc
interval in the daily clinical practices especially
during non-cardiovascular drug therapy. There are
many problems in the management of QT/QTc
interval because the targets of the treatment are not
cardiovascular diseases. Related problems are listed
in Table 3. Usually non-cardiovascular drugs are
prescribed by physicians who are not cardiology
specialists. These physicians will not attempt to
record ECGs before and after the prescription except
in the speciﬁc patients who have underlying cardi-
ovascular diseases, because they may not be familiar
with the clinical importance of QT/QTc prolonga-
tion induced by non-cardiovascular drugs.
Since automatic measurement of QT/QTc by the
built-in computers of ECG systems is sometimes
Table 1 Patient background that may aﬀect the electrocardiogram.
1. Cardiac dysfunction, heart failure, electrocardiographic abnormalities
2. Past and/or family history of arrhythmias, gender
3. Electrolyte imbalance (hypopotassemia, hypomagnesemia, etc.)
4. Bradycardias, tachycardias
5. Hypoproteinemia, anemia, diarrhea, dehydration
6. Liver dysfunction, renal dysfunction
7. Age (elderly or pediatric patients)
8. Autonomic nervous dysfunction, sleep disorder, mental stress
9. Excess alcohol, smoking
10. Drugs
Katoh T Drug-Induced Long QT Syndrome
57
inaccurate, especially under noisy conditions, a
physician with suﬃcient experience and knowledge
in accurately reading ECGs may be requested for the
appropriate evaluation of QT/QTc prolongation.7,8)
It is not easy to monitor QT/QTc intervals
thoroughly throughout a drug therapy. A certain
drug that has little eﬀect on QT/QTc interval
prolongation during the administration of a single
drug may exert signiﬁcant prolongation suddenly
with an unexpected elevation of the serum concen-
tration due to drug interaction when another drug is
prescribed concomitantly.
Table 2 Drugs that may prolong QT/QTc interval other than class III antiarrhythmic drugs.5Þ
Non-class III cardiovascular drugs Non-cardiovascular drugs
Sodium channel blockers Neuroleptics Antidepressants Antimicrobials Anticancer drugs
Quinidine Chlorpromazine Amitriptyline Erythromycin Anthracycline
Disopyramide Triﬂupromazine Protriptyline Co-trimoxazole Aclarubicin
N-acetyl-procainamide Promazine Nortriptyline Sulfamethoxazole 5-ﬂuorouracil
Lorcainide Perphenazine Butriptyline Pentamidine Acodazole
3-Methoxy-O-demethyl- Fluphenazine Desipramine Amantidine Adriamycin
encainide (MODE) Prochlorperazine Imipramine Grepaﬂoxacin Tamoxifen
Ajmaline Triﬂuoperazine Lofepramine Levoﬂoxacin S9788
Triethylperazine Clomipramine Moxiﬂoxacin 502U83
Antianginals Haloperidol Doxepin Sparﬂoxacin Arsenic trioxide
Prenylamine Triﬂuoperidol Maprotiline Gatiﬂoxacin Efavirenz
Fendiline Droperidol Dothiepin Clarithromycin
Lidoﬂazine Penﬂuridol Citalopram Spiramycin Miscellaneous
Bepridil Fluspirilene Zimeldine Fluconazole Vincamine
Aprindine Risperidone Fluoxetine D0870 Probucol
Terodiline Ziprasidone Antimoniates Glibenclamide
Perhexiline Amisulpride H1-Antihistamines Epoprostenol
Amiodarone Chlorprothixene Terfenadine Serotonin (5-HT2)-antagonists Chloral hydrate
Tedisamil Thiothixene Astemizole Ketanserin Amiloride
Mibefradil Thioridazine Diphenhydramine Amperozide Bromocriptine
Sertindole Promethazine Retanserin Sevoﬂurane
1=-blockers Pimozide Hydroxyzine Pipamperone Cisapride
Sotalol Zotepine Tacrolimus
Oxprenolol Quetiapine Antimalarials Serotonin (5-HT3)-antagonists Levacetylmethadol
Nifenalol Olanzapine Halofantrine Dolasetron Lubelozole
Indoramin Chloroquine Zatosetron Tiapride
Melperone Arteether Tizanidine
Amosulalol Rivastigmine
Cocaine
Inotropic agents Domperidone
Dobutamine Bupivacaine
Table 3 Problems in evaluation of QT interval under non-cardiovascular drug therapy.
1. Treatment target is not cardiovascular disease.
2. Attending doctor is not a cardiology specialist.
3. ECG will not be record before prescription of the drug.
4. ECG will not be record even after prescription of the drug.
5. Attending doctor may not be familiar with QT/QTc prolongation.
6. Accuracy of automatic measurement of QT interval is not always enough.
7. QT/QTc prolongation is sometimes concealed and may appear suddenly.
8. Unexpected prolongation may occur due to pharmacological interaction.
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Measurement of QT Interval
Recently, ICH-E14 reached step 5 agreement and
has requested that millisecond-level variation of QT
interval should be precisely detected using an
authorized method during clinical trials for all new
drugs even if they have little or no cardiovascular
eﬀect (thorough QT/QTc study).9–11) Thus, the
construction of an objective QT measurement system
with high quality and performance is urgently
needed to meet the request of ICH (cf. http://
www.ich.org).
Table 4 shows various methods that measure QT
interval in the clinical setting.12–19) An automatic
measurement using the built-in computer of ECG
machines will be the easiest way to measure a large
quantity of ECGs. However, the ICH does not
recommend it because of the questionable reliability
of the data. ICH requests a manual over-read system
to check the measured data by an authorized
cardiology specialist, especially in the early phase
of study for new drug development.20) Several
secondary analyses applying certain mathematical
approaches are expected as shown in Table 4. We are
studying the possibility of using the wavelet trans-
form analysis for the measurement of QT interval.21)
Since the wavelet analysis has a time- and frequen-
cy-domain nature, time-relevant information might
be preserved even during frequency analysis.22,23)
We believe that the method will be applicable for the
accurate measurement of QT interval in cases of ﬂat
or inverted T wave as illustrated in Figure 1, but
whether or not the method will be used is still under
consideration.
Determination of the Terminal Point of T
Wave
In the clinical setting, it is sometimes diﬃcult to
determine the real point of termination of the T wave
on the ECG not only due to noise, drift, and artifacts
Table 4 Methods to measure QT interval from the electrocardiogram.
1. Manual measurement
Using a manual caliper, paper speed with 50 mm/sec desirable, need skill and
time-consuming.
2. Automatic measurement
Using digital electrocardiography, automatically measured by built-in
computer, precisely measured but unstable with noise or drift.
3. Semi-automatic measurement
Using a digital caliper, displayed on the monitor, scanned data from paper-base
electrocardiogram, need some skill, time-consuming.
4. Measurement with mathematical adjustment
The ﬁrst-differentiated or the second-differentiated electrocardiogram,
time-frequency analysis using FFT or wavelet transform.
Z-lead Surface ECG Wavelet-transformed ECG 
405 msec 397 msec 
Figure 1 An example of wavelet analysis
of QT interval.
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but also due to ﬂattened or biphasic T waves or a
prominent U wave, depending upon the underlying
disease.24) It is very diﬃcult to measure QT intervals
in every beat with a high grade of accuracy.25)
There are many options as to the methods for
determining the terminal point of the T wave from
the ECG recordings. Among them the tangent
method and the threshold method are widely used.
It is known that the tangent method is slightly
superior in reproducibility of measurement and has
less inter-observer variation than the threshold
method. However, in case of biphasic or bizarre T
wave or severe baseline drift, a tangent line at the
down slope of the T wave sometimes cannot be
drawn appropriately. The threshold method can be
applied even in those cases. It is thought that in the
real world QT intervals are measured using both
methods on a case-by-case basis. It is better,
however, that these methods are not mixed during
the drug study if at all possible. A second method
should be used only to make corrections in case of
signiﬁcant discrepancies in the value of QT interval
measurement.
Before starting QT interval measurement, it is
essential to reach an agreement on the basic of
method where to draw the baseline and the tangent
line as illustrated in Figure 2.
Correction of Measured QT Interval (QTc)
QT intervals may ﬂuctuate frequently and instan-
taneously due to the change of various physiological
or pathological factors of the patients. Change of
heart rate is the main factor that may inﬂuence QT
interval. Many methods have been developed to
correct the QT interval for heart rate.26–32) The
measured QT intervals should be corrected by the
heart rate using several correction formulae as shown
in Table 5. Bazett’s formula (QTc = QT/RR1=2) is
most widely used. It is simple and easily applicable,
Over the signal or under the signal? Baseline was PP or QQ?
Terminal point of T wave? Baseline in case of severe drift?
Figure 2 How to draw the baseline and the
tangent line on the electrocardiogram.
Table 5 Various methods for correction of QT interval.
1. Bazett’s formula
QTcB = QT/RR1=2
2. Fridericia’s formula
QTcF = QT/RR1=3
3. Framingham’s formula
QTcFR = QT + 0.154(1-RR)
4. Individual linear regression method
QTcI = QT + b(1-RR)
5. RR bin method
Compare QT at HR 60–70/min before and after drug administration
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but the formula is aimed to adjust the QT interval
during a heart rate around 60 beats per minute.
However, Bazett’s formula becomes less accurate,
underestimating repolarization duration at slow heart
rates and overestimating at fast heart rates. It may
not be suitable for studies involving drugs that may
bring a great change of the heart rate. Fridericia’s
formula (QTc = QT/RR1=3) is also available. Com-
pared to Bazett’ formula, the overestimation at faster
heart rates is thought to be less and it is used most
frequently in the drug approval process. However,
the calculation process is more complicated. Several
new methods for correction of QT interval using
linear regression analysis have been recently applied.
If suﬃcient data of successive QT and RR intervals
are available to get the QT/RR relationship before
and after the study, QTcI might be the most reliable
correction method in individual patients. Another
approach to deal with QT interval is the so-called RR
bin method. When the stable Holter ECG before and
after the drug administration have been recorded,
absolute QT intervals at similar heart rates can
simply be compared without mathematical heart rate
corrections.
Thorough QT/QTc Study
According to the recently-issued ICH E-14 state-
ment, a ‘‘thorough QT/QTc study’’ is intended to
determine whether the drug has a threshold pharma-
cologic eﬀect on cardiac repolarization, as detected
by QT/QTc prolongation.10,11) The threshold level of
regulatory concern is around 5msec as evidenced by
an upper boundary of the 95% conﬁdence interval
around the mean eﬀect on QTc of 10msec. The
study is typically carried out in healthy volunteers
and is used to determine whether or not the eﬀect of
a drug on the QT/QTc interval in target patient
populations should be studied intensively during
later stages of drug development including phase II
and phase III clinical studies. It is not intended to
identify drugs as being pro-arrhythmic. The results
of the ‘‘thorough QT/QTc study’’ is not expected to
be aﬀected by ethnic factors.
Planning of the Clinical Trials in the Develop-
ment of New Drugs
Regardless of whether the drug is a cardiac or
non-cardiac agent, drug companies are requested to
perform an adequate pre-marketing investigation to
demonstrate safety, including detailed characteriza-
tion of the drug’s eﬀects on the QT/QTc interval in
humans.
ICH has recommended a rule in the clinical
evaluation of risk for QT/QTc prolongation in its
E14 documents. The recommendations contained in
this document are generally applicable to new drugs
having systemic bioavailability, but may not apply to
products with highly localized distribution and those
administered topically and not absorbed. Antiar-
rhythmic drugs known to prolong the QT/QTc
interval are excluded from this concept. Although
E14 is primarily concerned with the development of
new drugs, the recommendations might also be
applicable to approved drugs when a higher dose or a
new route of administration results in signiﬁcantly
higher exposure. Besides, the evaluation of QT
interval would also be considered important if the
drugs with similar pharmacological action have been
associated with QT/QTc interval prolongation, TdP,
or sudden cardiac death during post-marketing
surveillance.
Conclusion
I have raised the question at the beginning of this
review whether drugs are always fully responsible
for QT prolongation during medical therapy. Un-
fortunately, we have no deﬁnite answer to that
question. Because various non-pharmacological fac-
tors other than drugs used may have an inﬂuence on
the QT/QTc interval, we must be very careful in
evaluating ECG data during the clinical study of new
drugs. It is essential to plan studies elaborately in a
highly individualized manner taking into consider-
ation the characteristics of each drug.
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